UV0155041

Research use only, not for human use.

UV0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).

UV0155041 is a potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively).

VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons.

VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats.VU0155041 (93 nnmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480)-induced akinesia in rats. Animal Model:Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g) Dosage:31 nmol, 93 nmol (10 μL)Administration:Intracerebroventrical injection, after the Haloperidol (1.5 mg/kg) treatment 2 hours Result:Decreased the cataleptic effects of Haloperidol, and the effects still presented 30 min after infusion.

UV0155041 | UV-0155041 | UV 0155041

Others

Other Targets

mGluR4

——

——

1093757-42-6

316.18

C14H15Cl2NO3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (316.28 mM)

C1CC[C@H]([C@H](C1)C(=O)Nc1cc(cc(c1)Cl)Cl)C(=O)O

cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid

(-20℃)

With Ice Pack

≥ 2 years